1. Home
  2. COGT vs ENVA Comparison

COGT vs ENVA Comparison

Compare COGT & ENVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • ENVA
  • Stock Information
  • Founded
  • COGT 2014
  • ENVA 2011
  • Country
  • COGT United States
  • ENVA United States
  • Employees
  • COGT N/A
  • ENVA N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • ENVA Finance: Consumer Services
  • Sector
  • COGT Health Care
  • ENVA Finance
  • Exchange
  • COGT Nasdaq
  • ENVA Nasdaq
  • Market Cap
  • COGT 2.3B
  • ENVA 2.6B
  • IPO Year
  • COGT 2018
  • ENVA N/A
  • Fundamental
  • Price
  • COGT $36.63
  • ENVA $125.35
  • Analyst Decision
  • COGT Buy
  • ENVA Strong Buy
  • Analyst Count
  • COGT 13
  • ENVA 5
  • Target Price
  • COGT $28.08
  • ENVA $138.20
  • AVG Volume (30 Days)
  • COGT 4.8M
  • ENVA 236.4K
  • Earning Date
  • COGT 11-03-2025
  • ENVA 10-23-2025
  • Dividend Yield
  • COGT N/A
  • ENVA N/A
  • EPS Growth
  • COGT N/A
  • ENVA 73.62
  • EPS
  • COGT N/A
  • ENVA 10.82
  • Revenue
  • COGT N/A
  • ENVA $1,414,115,000.00
  • Revenue This Year
  • COGT N/A
  • ENVA $159.72
  • Revenue Next Year
  • COGT N/A
  • ENVA $16.16
  • P/E Ratio
  • COGT N/A
  • ENVA $11.48
  • Revenue Growth
  • COGT N/A
  • ENVA 20.78
  • 52 Week Low
  • COGT $3.72
  • ENVA $79.41
  • 52 Week High
  • COGT $37.08
  • ENVA $133.33
  • Technical
  • Relative Strength Index (RSI)
  • COGT 83.97
  • ENVA 55.60
  • Support Level
  • COGT $32.85
  • ENVA $119.02
  • Resistance Level
  • COGT $36.29
  • ENVA $128.49
  • Average True Range (ATR)
  • COGT 2.62
  • ENVA 4.98
  • MACD
  • COGT 1.10
  • ENVA -0.60
  • Stochastic Oscillator
  • COGT 98.45
  • ENVA 40.50

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About ENVA Enova International Inc.

Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.

Share on Social Networks: